Development of an intravenous desferrioxamine mesylate treatment protocol for swine: monitoring of desferrioxamine and metabolites by high-performance liquid chromatography.
Desferrioxamine (DFO) metabolism and its pharmacokinetics were studied in a swine model using high-performance liquid chromatography. DFO and three iron-binding metabolites occurred in plasma. Interindividual differences in pharmacokinetics and metabolism were observed. Urine analysis in 4 pigs showed three iron-binding metabolites. The mean percent dose excreted in urine in the form of the parent drug was 45 +/- 10% and 10 +/- 2% (means +/- SD) in the form of metabolites. Of the total amount of the parent drug infused, 3 h after initiation, 87% was in the form of DFO, whereas 13% was present as the DFO-iron III complex which represented 45 mg of urinary iron elimination. The described DFO infusion protocol provides for sufficient DFO to chelate significant amounts of ferric iron in excess of normal levels, thus allowing experimental studies of iron chelation in a variety of disease states.
Fisher
E A
EA
Department of Physiology, University of Toronto, Ont., Canada.
McLachlan
D R
DR
Kruck
T P
TP
Mustard
R A
RA
D000758:Anesthesia; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003676:Deferoxamine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D012128:Respiratory Distress Syndrome / Q000378:metabolism; D013552:Swine
D003676:Deferoxamine